Dextrose

證據等級: L5

預測適應症: 0 個

Dextrose: Drug Repurposing Evaluation Report

One-Sentence Summary

Dextrose (glucose) is a widely used pharmaceutical excipient and therapeutic agent, primarily administered as an intravenous fluid for caloric supply and hydration. The TxGNN model has not generated any repurposing predictions for this compound, and the evidence pack contains significant data gaps across all evaluation dimensions.

Quick Overview

Item	Content
Original Indication	Not available (license details incomplete)
Predicted New Indication	None — no predictions generated
TxGNN Prediction Score	N/A
Evidence Level	L5 (No prediction or supporting studies)
Malaysia Market Status	✓ Marketed
Number of Registrations	69
Recommended Decision	Hold

Why is This Prediction Reasonable?

No repurposing prediction was generated by the TxGNN model for Dextrose. This is likely due to the nature of the compound itself — Dextrose (D-glucose) is a simple monosaccharide used primarily as an energy substrate and vehicle for intravenous drug delivery, rather than a pharmacologically active drug with a specific molecular target. Its mechanism of action is based on fundamental metabolic pathways (glycolysis, cellular energy production) rather than a disease-specific therapeutic mechanism.

Because Dextrose lacks a targeted pharmacological mechanism, the TxGNN knowledge graph model may not identify meaningful disease–drug edges beyond its established nutritional and supportive-care roles. Compounds with broad, non-specific metabolic functions are generally poor candidates for indication-based repurposing, which relies on identifying novel target–disease relationships.

Additionally, the evidence pack is missing critical data including the detailed mechanism of action (MOA), DrugBank ID mapping, and approved indication text from regulatory filings. These data gaps further limit any meaningful repurposing analysis.

Clinical Trial Evidence

Currently no related clinical trials registered — no predicted indication was generated.

Literature Evidence

Currently no related literature available — no predicted indication was generated.

Malaysia Market Information

Authorization Number	Product Name	Dosage Form	Approved Indication
(Details not available)	—	—	—

Note: While 69 product registrations were identified in the NPRA database, the detailed license information (authorization numbers, product names, dosage forms, and approved indication text) was not populated in the evidence pack. Dextrose is commonly registered as an intravenous solution for fluid replacement, caloric supply, and as a vehicle for injectable medications.

Safety Considerations

Please refer to the package insert for safety information. Key warnings, contraindications, and drug interaction data were not available in the current evidence pack.

Conclusion and Next Steps

Decision: Hold

Rationale: No repurposing prediction was generated by the TxGNN model for Dextrose. The compound functions as a basic metabolic substrate rather than a targeted therapeutic agent, making it an unlikely candidate for indication-based drug repurposing. Additionally, the evidence pack contains multiple blocking data gaps that prevent meaningful evaluation.

To proceed, the following is needed:

Resolve DrugBank ID mapping (query returned 1 result but ID was not captured)
Populate NPRA license details (authorization numbers, product names, approved indications) for the 69 registered products
Obtain TFDA package insert warnings and contraindications (severity: Blocking — DG001)
Obtain mechanism of action data from DrugBank (severity: High — DG002)
Re-evaluate whether Dextrose, as a non-targeted metabolic compound, is an appropriate candidate for the TxGNN repurposing pipeline

Disclaimer: This report is for research purposes only and does not constitute medical advice. Any drug repurposing candidates require clinical validation before application.

Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.